Approval · Notice of Compliance 29951 · 2023
TEVA-CEFADROXIL: Notice of Compliance 29951
Issued January 20, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29951
- Date
- January 20, 2023
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to labels. Change in the drug product manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-CEFADROXIL | Not yet assigned | — |
Medicinal ingredients
- CEFADROXIL MONOHYDRATE 500 MG per CAP